Terlipressin as rescue treatment of refractory shock in a neonate

2008 ◽  
Vol 97 (4) ◽  
pp. 500-501 ◽  
Author(s):  
Luca Filippi ◽  
Chiara Poggi ◽  
Lisa Serafini ◽  
Patrizio Fiorini
2020 ◽  
Vol 57 (9) ◽  
pp. 864-865
Author(s):  
Ignacio Oulego-Erroz ◽  
Sandra Terroba-Seara ◽  
Leticia Castanon-Lopez ◽  
Antonio Rodriguez-Nunez

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 129-LB
Author(s):  
SANJAY K. BAJPAI ◽  
JANELLE CAMBRON-MELLOTT ◽  
NEDINA K. RAIBULET ◽  
EUGENIA Y. PECK ◽  
JIAT LING POON ◽  
...  

2021 ◽  
Vol 93 (6) ◽  
pp. AB244-AB245
Author(s):  
Cecilia Binda ◽  
Andrea A. Anderloni ◽  
Alessandro Fugazza ◽  
Arnaldo Amato ◽  
Germana De Nucci ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Chao-Hung Kuo ◽  
Fu-Chen Kuo ◽  
Huang-Ming Hu ◽  
Chung-Jung Liu ◽  
Sophie S. W. Wang ◽  
...  

This paper reviews the literature about first-line therapies forH. pyloriinfection in recent years. First-line therapies are facing a challenge because of increasing treatment failure due to elevated antibiotics resistance. Several new treatment strategies that recently emerged to overcome antibiotic resistance have been surveyed. Alternative first-line therapies include bismuth-containing quadruple therapy, sequential therapy, concomitant therapy, and hybrid therapy. Levofloxacin-based therapy shows impressive efficacy but might be employed as rescue treatment due to rapidly raising resistance. Rifabutin-based therapy is also regarded as a rescue therapy. Several factors including antibiotics resistance, patient compliance, and CYP 2C19 genotypes could influence the outcome. Clinicians should use antibiotics according to local reports. It is recommended that triple therapy should not be used in areas with high clarithromycin resistance or dual clarithromycin and metronidazole resistance.


2021 ◽  
Vol 14 (1) ◽  
pp. e238120
Author(s):  
Christopher Houle ◽  
Varun Reddy

This report describes a patient who developed intraprocedural vascular stasis immediately following elective endovascular coil emboliation. Urgent antiplatelet treatment with the GpIIb/IIIa agent tirofiban was used. It was infused intra-arterially during the procedure, followed by a fixed rate intravenous continuous infusion, and successfully restored normal circulation. There were no reports of further bleeding or haemodynamic compromise during the hospital stay. The patient’s condition returned to baseline and he was discharged the following day with no neurological deficits.


2021 ◽  
Vol 40 (9) ◽  
pp. 2257-2271
Author(s):  
Hege Michiels ◽  
Cristina Sotto ◽  
An Vandebosch ◽  
Stijn Vansteelandt

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ryoung-Eun Ko ◽  
Chi Ryang Chung ◽  
Jeong Hoon Yang ◽  
Kyeongman Jeon ◽  
Gee Young Suh ◽  
...  

AbstractAlthough extracorporeal membrane oxygenation (ECMO) is increasingly utilized, only a limited level of experience has been reported in postpartum cardiopulmonary failure. Ten critically ill postpartum patients who received ECMO were included between January 2010 and December 2018 in this retrospective observational study. The main indication for ECMO support was peripartum cardiomyopathy (n = 5), followed by postpartum hemorrhage (n = 2). Nine patients initially received veno-arterial ECMO, and one patient received veno-venous ECMO. Major bleeding occurred in six patients. The median number of units of red blood cells (RBC) transfused during ECMO was 14.5 units (interquartile range 6.8–37.8 units), and most RBC transfusions occurred on the first day of ECMO. The survival-to-discharge rate was 80%. Compared to the survival outcomes in female patients of similar age who received ECMO, the survival outcomes were significantly better in the study population (56% versus 80%, P = 0.0004). Despite the high risk of major bleeding, ECMO for patients with postpartum cardiac or respiratory failure showed excellent survival outcomes. ECMO is feasible in these patients and can be carried out with good outcomes in an experienced centre.


Sign in / Sign up

Export Citation Format

Share Document